Mary Louise Keohan

8PUBLICATIONS
98CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)ChemotherapyPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 12, 2026
Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand

|Dec 01, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

Evan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar

|Jul 22, 2025
ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor.

Ciara M Kelly, Martina Bradic, Sara Saunds

|Oct 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.

Sujana Movva, Kenneth Seier, Viswatej Avutu

|Oct 03, 2023
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced Sarcomas.

Evan Rosenbaum, Kenneth Seier, Martina Bradic

|Sep 11, 2023
Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma.

Caroline E Gleason, Mark A Dickson, Mary E Klein Dooley

Pageof 2

Frequent Collaborators

8 joint publications

Sujana Movva

7 joint publications

Li-Xuan Qin

7 joint publications

Sandra P D'Angelo

7 joint publications

Ciara M Kelly